ArticleBasic & clinical pharmacology & toxicology2026
Trends in Antithrombotic Therapy Initiation Among Patients With Stroke Pre- and Post-COVID-19 in Sweden-An Interrupted Time Series Study.
Article in Basic & clinical pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends in Antithrombotic Therapy Initiation Among Patients With Stroke Pre- and Post-COVID-19 in Sweden-An Interrupted Time Series Study.Basic & clinical pharmacology & toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAntithrombotic therapy constitutes a critical part of stroke management, and its utilization serves as an important indicator in the assessment of stroke care. However, knowledge on how the pandemic influenced the antithrombotic utilization after stroke remains limited.
objectiveThis study aims to investigate the impact of the COVID-19 pandemic on the initiation of antithrombotic agents after stroke in Sweden.
designUsing nationwide linked Swedish health registers, we conducted an interrupted time series analysis (ITSA) using generalized linear model (binomial distribution, logit link). We estimated monthly trends in the initiation of antithrombotic drugs among new stroke patients between January 2019 and April 2024, with the pandemic intervention point set in March 2020. KEY
resultsThe monthly number of stroke cases declined significantly by 107 cases per month. No significant changes were observed in the total antithrombotic initiation. Antiplatelets showed a significant pre-pandemic increasing trend (OR = 1.011 per month, 95% CI: 1.003 to 1.020), an immediate level increase at onset (OR = 1.150, 95% CI: 1.067 to 1.259) and a post-intervention decline (OR = 0.991 per month, 95% CI: 0.981 to 0.998). Factor Xa inhibitors use increased post-intervention (OR = 1.004, 95% CI: 1.002 to 1.006), while warfarin (OR = 0.990, 95% CI: 0.981 to 0.999) and dabigatran (OR = 0.991, 95% CI: 0.986 to 0.997) decreased.
conclusionsThe COVID-19 pandemic had no impact on the overall use of antithrombotic agents. However, a short-term increase in antiplatelet initiation and long-term changes in warfarin, dabigatran, and factor Xa initiations were observed after the COVID-19 outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.